Oral Anticancer Medication Coverage Law

Effective as of July 15, 2012, New Jersey Public Law, 2011, C. 188, requires health insurance carriers to cover oral anticancer medications “on a basis no less favorable than intravenous anticancer medications.” That means coverage for specific prescribed anticancer medications is not subject to any prior authorizations, dollar limitations, deductibles, copayments or coinsurance that do not apply to intravenously administered or injected anticancer medications.

Orally administered anticancer medicines are prescription medicines that: (a) are used to slow or kill the growth of cancerous cells, and (b) are given orally (by mouth). Such medicines do not include those that:

• Are prescribed to maintain red or white cell counts.
• Treat nausea.
• Are prescribed to support the anticancer prescription medicines. This List includes the medicines that are approved under this mandate.

Last Updated: 01/01/2023

This document contains references to brand name prescription medicines that are trademarks or registered marks of pharmaceutical manufacturers that are not affiliated with
Horizon Blue Cross Blue Shield of New Jersey or the Blue Cross and Blue Shield Association.
Horizon Blue Cross Blue Shield of New Jersey is an independent licensee of the Blue Cross and Blue Shield Association.
The Blue Cross® and Blue Shield® names and symbols are registered marks of the Blue Cross and Blue Shield Association.
The Horizon® name and symbols are registered marks of Horizon Blue Cross Blue Shield of New Jersey.
© 2020 Horizon Blue Cross Blue Shield of New Jersey. Three Penn Plaza East, Newark, New Jersey 07105.